Zanidatamab + Letrozole + Tamoxifen
Phase 2Recruiting 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, HER2-positive
Trial Timeline
Nov 16, 2021 → Dec 29, 2028
NCT ID
NCT05035836About Zanidatamab + Letrozole + Tamoxifen
Zanidatamab + Letrozole + Tamoxifen is a phase 2 stage product being developed by Zymeworks for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05035836. Target conditions include Breast Cancer, HER2-positive.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05035836 | Phase 2 | Recruiting |
Competing Products
20 competing products in Breast Cancer